Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Evaluation of the population safety of nonsteroidal anti-inflammatory drugs in the framework of the Pan-European SOS program: focus on aceclofenac

https://doi.org/10.14412/2074-2711-2020-2-109-113

Full Text:

Abstract

Since 2008, a group of international experts has been studying the population risk of serious complications of NSAIDs (the Safety Of nonSteroidal anti-inflammatory drugs (SOS) project) as part of the Seventh Framework Program of the European Union for Research and Technological Development (2007–2013). Four large-scale studies assessing the individual risk of gastrointestinal bleeding, heart failure (HF), ischemic stroke (IS), and myocardial infarction (MI) while taking various NSAIDs have been published over the past time. Meta-analysis of 28 population studies has shown that the risk of bleeding is minimal for aceclofenac: the relative risk is 1.43 (95% confidence interval (CI), 0.65–3.15). Analysis of national databases in the Netherlands, Italy, Germany, and the UK has indicated that aceclofenac does not increase the risk of hospitalization for heart failure (odds ratio (OR), 1.03; 95% CI, 0.91–1.15) and MI (OR, 1.04; 95% CI, 0.90–1.19). The risk of IS from the use of aceclofenac is slightly increased (OR, 1.17; 95% CI, 0.98–1.39), but is not statistically significant. Thus, according to the Pan-European SOS program, aceclofenac is characterized by a very low risk of gastrointestinal and cardiovascular events.

About the Author

A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115552, Russia





References

1. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.

2. De Lima L, Radbruch L. The International Association for Hospice and Palliative Care: Advancing Hospice and Palliative Care Worldwide. J Pain Symptom Manage. 2018 Feb;55(2S):S96-S103. doi: 10.1016/j.jpainsymman.2017.03.023. Epub 2017 Aug 8.

3. Rasu RS, Vouthy K, Crowl AN, et al. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. J Manag Care Spec Pharm. 2014 Sep; 20(9):921-8.

4. Brennan F, Carr D, Cousins M. Access to Pain Management-Still Very Much a Human Right. Pain Med. 2016 Oct;17(10):1785-1789.

5. Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Prev Med. 2019 Jun; 123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

6. Lohman D, Schleifer R, Amon JJ. Access to pain treatment as a human right. BMC Med. 2010 Jan 20;8:8. doi: 10.1186/1741-7015-8-8.

7. Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.

8. Abbasi AB, Salisbury-Afshar E, Berberet CE, et al. Opioid Prescribing Patterns Before Fatal Opioid Overdose. Am J Prev Med. 2020 Feb; 58(2):250-253. doi: 10.1016/j.amepre.2019.09.022.

9. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000.

10. Shipton EA, Shipton EE, Shipton AJ. A Review of the Opioid Epidemic: What Do We Do About It? Pain Ther. 2018 Jun;7(1):23-36. doi: 10.1007/s40122-018-0096-7. Epub 2018 Apr 6.

11. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28; 354:i4857. doi: 10.1136/bmj.i4857.

12. Trouvin AP, Berenbaum F, Perrot S. The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open. 2019 Aug 6;5(2):e001029. doi: 10.1136/rmdopen-2019-001029. eCollection 2019.

13. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.

14. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.

15. Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.

16. Rasu RS, Vouthy K, Crowl AN, et al. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. J Manag Care Spec Pharm. 2014 Sep; 20(9):921-8.

17. List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu

18. Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Prev Med. 2019 Jun; 123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

19. https://www.drugs.com/international/aceclofenac.html

20. Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.

21. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.

22. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000.

23. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.

24. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28; 354:i4857. doi: 10.1136/bmj.i4857.

25. Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105

26. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.

27. Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94

28. Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.

29. List of nationally authorised medicinal products. Active substance(s): aceclofenac. 30 November 2017 EMA/787572/2017 Human Medicines Evaluation Division. https://www.ema.europa.eu

30. https://www.drugs.com/international/aceclofenac.html

31. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.

32. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.

33. Igolkina EV, Chichasova NV, Imametdinova GR. Aceclofenac in the treatment of diseases of the locomotor apparatus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(3):99-105. (In Russ.). doi: 10.14412/1996-7012-2017-3-99-105

34. Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi: 10.14412/1996-7012-2017-4-89-94


For citation:


Karateev A.E. Evaluation of the population safety of nonsteroidal anti-inflammatory drugs in the framework of the Pan-European SOS program: focus on aceclofenac. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):109-113. (In Russ.) https://doi.org/10.14412/2074-2711-2020-2-109-113

Views: 51


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)